Analysts estimate that Precision BioSciences will report an earnings per share (EPS) of $-2.42. Precision BioSciences bulls ...

Precision BioSciences (NASDAQ:DTIL) is scheduled to announce Q1 earnings results on Thursday, May 15th, before market open. The consensus EPS Estimate is -$2.42 (-242.4% Y/Y) and the consensus Revenue ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet ...

Comparatively, 38.0% of Precision BioSciences shares are owned by institutional investors. 60.9% of Scinai Immunotherapeutics shares are owned by company insiders. Comparatively, 4.0% of Precision ...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...

Detailed price information for Precision Biosciences Inc (DTIL-Q) from The Globe and Mail including charting and trades.

MBX Biosciences, Inc.’s MBX share price has dipped by 5.72%, which has investors questioning if this is right time to buy.

DURHAM, N.C., May 07, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...